References
- Substance abuse and mental health services administration. Results from the 2009 national survey on drug use and health: volume I. summary of national findings. Office of applied studies, NSDUH series H-38A. HHS publication no SMA 10-4586 Findings, Rockville, MD, 2010
- Friedman RA. (2006). The changing face of teenage drug abuse–the trend toward prescription drugs. N Engl J Med, 354:1448–1450.
- Substance abuse and mental health services administration. Treatment episode data set (TEDS): 1998-2008. State admissions to substance abuse treatment services. Center for behavioral health statistics and quality, DASIS series: S-55. HHS publication no (SMA) 10-4613, Rockville, MD, 2010
- American pain society. (1996). Advocacy: the use of opioids for the treatment of chronic pain, a consensus statement from American academy of pain medicine and American pain society [Online]. Available at: http://www.ampainsoc.org/advocacy/opioids.htm. Accessed on 22 March 2011.
- Friedman RA. (2006). The changing face of teenage drug abuse–the trend toward prescription drugs. N Engl J Med, 354:1448–1450.
- Manchikanti L. (2007). National drug control policy and prescription drug abuse: facts and fallacies. Pain Physician, 10:399–424.
- Substance abuse and mental health services administration. Results from the 2008 national survey on drug use and health: national findings. Office of applied studies, NSDUH series H-36. HHS publication no SMA 09-4434 Rockville, MD, 2009
- Ford JA, Lacerenza C. (2011). The relationship between source of diversion and prescription drug misuse, abuse, and dependence. Subst Use Misuse, 46:819–827.
- The national center on addiction and substance abuse (CASA) at Columbia University. Under the counter: the diversion and abuse of controlled prescription drugs in the US New York, NY, 2005. Available at: http://www.casacolumbia.org/articlefiles/380-Under%20the%20Counter%20-%20Diversion.pdf. Accessed on 15 February 2011.
- Johnston LD, O’Malley PM, Bachman JG, et al. (2011). Monitoring the future, national results on adolescent drug use: overview of key findings, 2010 [Online]. Institute for social research, University of Michigan, Ann Arbor. Available at: http://www.monitoringthefuture.org/pubs/monographs/mtf-overview2010.pdf. Accessed on 18 March 2011.
- Levine SB, Coupey SM. (2009). Nonmedical use of prescription medications: an emerging risk behavior among rural adolescents. J Adolesc Health, 44:407–409.
- Substance abuse and mental health services administration. Center for behavioral health statistics and quality. The DAWN report: drug-related emergency department visits involving pharmaceutical misuse and abuse by older adults. Rockville, MD, 2010. Available at: http://www.samhsa.gov/data/2k10/WebSR018Pharma50+/Pharma50+HTML.pdf. Accessed on 19 March 2011.
- Center for lawful access and abuse deterrence. (2009). The national prescription drug abuse prevention strategy 2009 [Online]. Available at: http://claad.org/downloads/Nat_Prescipt_Drug_Abuse_Prev_Strat_2009.pdf. Accessed on 17 March 2011.
- Schneider JP, Matthews M, Jamison RN. (2010). Abuse-deterrent and tamper-resistant opioid formulations: what is their role in addressing prescription opioid abuse? CNS Drugs, 24:805–810.
- Katz NP, Adams EH, Chilcoat H, Colucci RD, Comer SD, Goliber P et al. (2007). Challenges in the development of prescription opioid abuse-deterrent formulations. Clin J Pain, 23:648–660.
- National association of drug diversion investigators inc. (2011). Abused pharmaceutical substances [Online]. Available at: http://naddi.associationdatabase.com/aws/NADDI/pt/sp/abused_rx. Accessed on 22 March 2011.
- National institute on drug abuse. (2009). NIDA InfoFacts: prescription and over-the-counter medications [Online]. Available at: http://www.drugabuse.gov/PDF/Infofacts/PainMed09.pdf. Accessed on 25 February 2011.
- Foye WO, Lemke TL, Williams DA. Foye’s principles of medicinal chemistry. 6th ed. Series. Philadelphia: Lippincott Williams & Wilkins, 2008:652–653.
- Skerritt JH, Johnston GA. (1983). Enhancement of GABA binding by benzodiazepines and related anxiolytics. Eur J Pharmacol, 89:193–198.
- Sulzer D, Sonders MS, Poulsen NW, Galli A. (2005). Mechanisms of neurotransmitter release by amphetamines: a review. Prog Neurobiol, 75:406–433.
- The national institute on drug abuse. (2007). Methamphetamine addiction: cause for concern—hope for the future [Online]. Available at: http://www.drugabuse.gov/tib/meth.html. Accessed on 22 March 2011.
- Passik SD, Hays L, Eisner N, Kirsh KL. (2006). Psychiatric and pain characteristics of prescription drug abusers entering drug rehabilitation. J Pain Palliat Care Pharmacother, 20:5–13.
- McCabe SE, Cranford JA, Morales M, Young A. (2006). Simultaneous and concurrent polydrug use of alcohol and prescription drugs: prevalence, correlates, and consequences. J Stud Alcohol, 67:529–537.
- US Food and Drug Administration. (2005). Information for healthcare professionals: hydromorphone hydrochloride extended-release capsules (marketed as Palladone), [Online]. Available at: http://www.fda.gov/Drugs/DrugSafety/Postmarket DrugSafetyInformationforPatientsandProviders/ucm129288.htm. Accessed on 4 April 2011.
- Jayawant SS, Balkrishnan R. (2005). The controversy surrounding OxyContin abuse: issues and solutions. Ther Clin Risk Manag, 1:77–82.
- Meng Y, Lichtman AH, Bridgen DT, Martin BR. (1997). Inhalation studies with drugs of abuse. NIDA Res Monogr, 173:201–224.
- Prosser JM, Jones BE, Nelson L. (2010). Complications of oral exposure to fentanyl transdermal delivery system patches. J Med Toxicol, 6:443–447.
- Marquardt KA, Tharratt RS, Musallam NA. (1995). Fentanyl remaining in a transdermal system following three days of continuous use. Ann Pharmacother, 29:969–971.
- Cone EJ. (2006). Ephemeral profiles of prescription drug and formulation tampering: evolving pseudoscience on the Internet. Drug Alcohol Depend, 83 Suppl 1:S31–S39.
- Goldberg AP. Transdermal delivery form disposal systems and methods. US patent application no.12/048771 (2008).
- Marcenyac G, Alfonso M, Gehrlein L, et al. Disposal system for transdermal dosage form. US patent application no.10/476032 (2002).
- Anderson CR, Morris RL, Anderson C, et al. Abuse potential reduction in abusable substance dosage form. US7867511 (2011).
- Tavares L, Reidenberg BE, Sackler RS, et al. Abuse resistant opioid containing transdermal systems. US patent application no.10/476601 (2002).
- US Food and Drug Administration. (2009). Risk evaluation and mitigation strategies (REMS) and opioid analgesics webinar [Online]. Available at: http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm163655.htm. Accessed on 23 March 2011.
- Woodcock J. A difficult balance—pain management, drug safety, and the FDA. N Engl J Med 2009; 361:2105–7.
- US Food and Drug Administration. (2009). Background on opioid REMS [Online]. Available at: http://www.fda.gov/drugs/drugsafety/informationbydrugclass/ucm187975. Accessed on 23 March 2011.
- Center for drug evaluation and research. (2010). (Draft) Guidance for industry, assessment of abuse potential of drugs [Online]. US Food and Drug Administration. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM198650.pdf. Accessed on 16 January 2011.
- Tolliver JM. (2010). Premarketing assessment of abuse deterrent formulations [Online]. Center for Drug Evaluation and Research, US Food and Drug Administration. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AnestheticAndLifeSupportDrugsAdvisoryCommittee/UCM 233240.pdf. Accessed on 23 March 2011.
- Hamed E, Moe D. Development of tamper deterrent formulations: state of the pharmaceutical industry. Curr Drug Abuse Rev 2010; 3:139–146.
- Webster L. Update on abuse-resistant and abuse-deterrent approaches to opioid formulations. Pain Med 2009; 10 Suppl 2:S124–33.
- Coleman JJ, Schuster CR, DuPont RL. Reducing the abuse potential of controlled substances. Pharmaceutical Medicine 2010; 24:21–36.
- Hirsh JC, Fleming AB, Rariy RV, et al. Abuse-deterrent drug formulations. US7771707 (2010).
- Cicero TJ, Inciardi JA, Muñoz A. (2005). Trends in abuse of Oxycontin and other opioid analgesics in the United States: 2002–2004. J Pain, 6:662–672.
- US Food and Drug Administration. (2010). FDA approves new formulation for OxyContin® [Online]. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm207480.htm. Accessed on 17 January 2011.
- Purdue Pharma L.P. (2011). Purdue’s prescription drug products [Online]. Available at: http://www.purduepharma.com/Products/Prescription/Pages/default.aspx. Accessed on 23 March 2011.
- Purdue Pharma L.P. (2008). Purdue meeting background materials, NDA 22-272 reformulated OxyContin®, joint meeting of the anesthetic and life support drugs advisory committee and drug safety and risk management advisory committee [Online]. Available at: http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4356b1-02-Purdue.pdf. Accessed on 14 April 2011.
- DURECT Corporation. ORADUR® gel cap system [Online]. Available at: http://www.durect.com/wt/durect/page_name/oradur. Accessed on 14 January 2011.
- Lu Y, Yu Y, Tang X. (2007). Sucrose acetate isobutyrate as an in situ forming system for sustained risperidone release. J Pharm Sci, 96:3252–3262.
- Pain Therapeutics Inc. (2008). NDA 22-324 Remoxy XRT, advisory committee briefing materials for the anesthetic life support drugs advisory committee meeting of November 13, 2008 [Online]. Available at: http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4395b1-02-PAIN.pdf. Accessed on 17 March 2011.
- Zamloot M, Chao W, Kang LL, et al. Remoxy®: a novel formulation of extended release oxycodone developed using the ORADUR® technology. J Appl Res 2010;10:88–96.
- Friedmann N, Butera P, Klutzaritz V, et al. (2008). Remoxy, an abuse-resistant controlled-release oxycodone, treats chronic pain [Online]. Available at: http://www.paintrials.com/publications/Remoxy_PTI-821-CO.pdf. Accessed on 27 March 2011.
- Gilderman L, Butera PG, Gilmore D, et al. (2006). Remoxy™: a new opioid drug with effective analgesia and abuse-resistance [Online]. Available at: http://www.paintrials.com/aps/Remoxy_APSposter.pdf. Accessed on 27 March 2011.
- Pain Therapeutics Inc. (2011). FDA complete response letter received for REMOXY [Online]. Available at: http://investor.paintrials.com/releasedetail.cfm?ReleaseID=587311. Accessed on 20 March 2011.
- DuPont RL, Lande SD. The impact of abuse deterrent formulation on the incidence of abuse and diversion of OROSOR methylphenidate. Drug Alcohol Depend 2006; 83:S87.
- Parasrampuria DA, Schoedel KA, Schuller R, Silber SA, Ciccone PE, Gu J et al. (2007). Do formulation differences alter abuse liability of methylphenidate? A placebo-controlled, randomized, double-blind, crossover study in recreational drug users. J Clin Psychopharmacol, 27:459–467.
- Shannon HE, Su TP. (1982). Effects of the combination of tripelennamine and pentazocine at the behavioral and molecular levels. Pharmacol Biochem Behav, 17:789–795.
- Reed DA, Schnoll SH. (1986). Abuse of pentazocine-naloxone combination. JAMA, 256:2562–2564.
- Lahmeyer HW, Craig RJ. (1987). Pentazocine–naloxone: another “addiction-proofâ drug of abuse. Int J Addict, 22:1163–1166.
- Reckitt Benckiser Pharmaceuticals Inc. (2011). SUBOXONE film, key benefits [Online]. Available at: http://www.suboxone.com/hcp/about_suboxone/key_benefits.aspx. Accessed on 25 March 2011.
- Greene P. (2010). Outpatient drug utilization trends for buprenorphine years 2002-2009, US Food and Drug Administration, division of epidemiology [Online]. Available at: http://buprenorphine.samhsa.gov/bwns/2010_presentations_pdf/09_Greene_508.pdf. Accessed on 5 March 2011.
- Stinchcomb AL, Golinski MJ, Hammell DC, et al. Transdermally deliverable opioid prodrugs, abuse-resistant compositions and methods of using opioid prodrugs. US7511054 (2009).
- Oshlack B, Wright C, Haddox JD. Tamper-resistant oral opioid agonist formulations US7842311 (2010).
- Sackler R. Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant. US7332182 (2008).
- Oshlack B, Wright C, Breder C. Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent. US7842307 (2010).
- King Pharmaceuticals Inc. (2009). EMBEDA® prescribing information [Online]. Available at: http://www.kingpharm.com/products/product_document.cfm?brand_name=Embeda&product_specific_name=CII&document_type_code=PI. Accessed on 20 April 2011.
- King Pharmaceuticals Inc. (2011). EMBEDA® important information for patients and prescribers [Online]. Available at: http://www.embeda.com/. Accessed on 24 March 2011.
- Alpharma Pharmaceuticals LLC. (2010). EMBEDA® extended release capsules: joint anesthetic and life support drugs (ALSDAC) and drug safety and risk management (DSaRM) advisory committee briefing document [Online]. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AnestheticAndLifeSupportDrugsAdvisoryCommittee/UCM230111.pdf. Accessed on 3 March 2011.
- Passik SD. (2009). Issues in long-term opioid therapy: unmet needs, risks, and solutions. Mayo Clin Proc, 84:593–601.
- Dew RE, Kollins SH. (2010). Lisdexamfetamine dimesylate: a new option in stimulant treatment for ADHD. Expert Opin Pharmacother, 11:2907–2913.
- Jasinski DR, Krishnan S. (2009). Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse. J Psychopharmacol (Oxford), 23:419–427.
- Mickle T, Krishnan S, Moncrief JS, et al. Abuse-resistant hydrocodone compounds. US7375082 (2008).
- Ruan X, Chen T, Gudin J, Couch JP, Chiravuri S. (2010). Acute opioid withdrawal precipitated by ingestion of crushed embeda (morphine extended release with sequestered naltrexone): case report and the focused review of the literature. J Opioid Manag, 6:300–303.
- Bear D. Material for controlling diversion of medications. US7226619 (2007).
- Pfizer Inc. (2005). Lomotil® US Physician Prescribing Information [Online]. Available at: http://www.pfizer.com/files/products/uspi_lomotil.pdf. Accessed on 23 March 2011.
- Acura Pharmaceuticals Inc. (2011). Acurox® with niacin tablets [Online]. Available at: http://acurapharm.com/products/acurox-tablets/. Accessed on 18 March 2011.
- Acura Pharmaceuticals Inc. (2011). Study AP-ADF-107, a phase II single-center, randomized, double-blind study in fasted and non-fasted healthy volunteers to evaluate the dose response for flushing and safety and tolerability of escalating doses of niacin [Online]. Available at: http://acurapharm.com/products/acurox-tablets/study-ap-adf-107/. Accessed on 18 March 2011.
- Davidson MH. Niacin use and cutaneous flushing: Mechanisms and strategies for prevention. Am J Cardiol 2008; 101:14B–19B.
- Xanodyne Pharmaceuticals Inc. (2008). Roxicodone® prescribing information [Online]. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021011s002lbl.pdf. Accessed on 25 March 2011.
- Kumar V, Dixon D, Tewari D, et al. Methods and compositions for deterring abuse of opioid containing dosage forms. US7476402 (2009).
- Kumar V, Dixon D, Tewari D, et al. Methods and compositions for deterring abuse of opioid containing dosage forms. US7510726 (2009).
- Kumar V, Dixon D, Tewari D, et al. Methods and compositions for deterring abuse of opioid containing dosage forms. US7201920 (2007).
- Oshlack B, Colucci R, Wright C, et al. Pharmaceutical formulation containing opioid agonist, opioid antagonist and bittering agent. US7144587 (2006).
- Frank ME, Bouverat BP, MacKinnon BI, Hettinger TP. (2004). The distinctiveness of ionic and nonionic bitter stimuli. Physiol Behav, 80:421–431.
- Brushwood DB, Rich BA, Coleman JJ, Bolen J, Wong W. (2010). Legal liability perspectives on abuse-deterrent opioids in the treatment of chronic pain. J Pain Palliat Care Pharmacother, 24:333–348.
- Katz N. (2008). Abuse-deterrent opioid formulations: are they a pipe dream? Curr Rheumatol Rep, 10:11–18.
- Fishman SM, Papazian JS, Gonzalez S, Riches PS, Gilson A. (2004). Regulating opioid prescribing through prescription monitoring programs: balancing drug diversion and treatment of pain. Pain Med, 5:309–324.
- Acura Pharmaceuticals Inc. (2011). Impede™ technology [Online]. Available at: http://acurapharm.com/research-development/impede-technology/. Accessed on 25 March 2011.
- European medicines agency.Committee for medicinal products for human use (CHMP). Guideline on clinical development of fixed combination medicinal products. 2009; CHMP/EWP/ 240/95.
- European medicines agency. (2006). Suboxone: EPAR-Scientific Discussion [Online]. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000697/WC500058497.pdf. Accessed on 28 Dec 2011.
- Johnson F, Ciric S, Boudriau S, Swearingen D, Stauffer J. (2010). Food effects on the pharmacokinetics of morphine sulfate and naltrexone hydrochloride extended release capsules. Adv Ther, 27:846–858.
- Stauffer J, Setnik B, Sokolowska M, Romach M, Johnson F, Sellers E. (2009). Subjective effects and safety of whole and tampered morphine sulfate and naltrexone hydrochloride (ALO-01) extended-release capsules versus morphine solution and placebo in experienced non-dependent opioid users: a randomized, double-blind, placebo-controlled, crossover study. Clin Drug Investig, 29:777–790.
- Raffa RB, Pergolizzi JV Jr. (2010). Opioid formulations designed to resist/deter abuse. Drugs, 70:1657–1675.
- Lennernäs H. (2009). Ethanol-drug absorption interaction: potential for a significant effect on the plasma pharmacokinetics of ethanol vulnerable formulations. Mol Pharm, 6:1429–1440.